Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ligand PharmaceuticalsFRA:LGDN 76 3-Year EBITDA Growth Rate is 22.50% as of Jun. 2026, which is 29% above its 10-year median of 17.45. GuruFocus rates FRA:LGDN with a GF Score™ of 76/100 and a GF Value™ of €154.08 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 1,130 Biotechnology companies, Ligand Pharmaceuticals ranks better than 59.03% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 22.50% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 4.20% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 9.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Ligand Pharmaceuticals was 206.40% per year. The lowest was -602.40% per year. And the median was 17.45% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Ligand Pharmaceuticals 3-Year EBITDA Growth Rate Related Terms
FRA:LGDN vs CGON, DFTX, XENE: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Ligand Pharmaceuticals's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ligand Pharmaceuticals 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ligand Pharmaceuticals's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Ligand Pharmaceuticals's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 22.50% mean?
Ligand Pharmaceuticals (FRA:LGDN) has a 3-Year EBITDA Growth Rate of 22.50% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Ligand Pharmaceuticals and its competitors. This is 29% above median its historical median of 17.45. According to the industry distribution chart, Ligand Pharmaceuticals ranks #463 out of 1130 companies in the Biotechnology industry, placing it in the top 41%.
Is Ligand Pharmaceuticals' 3-Year EBITDA Growth Rate too high?
Ligand Pharmaceuticals' current 3-Year EBITDA Growth Rate of 22.50% is 29% above median its 10-year median of 17.45. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.85. Ligand Pharmaceuticals' value of 22.50% is 51.5% above this industry median. Based on the distribution chart, Ligand Pharmaceuticals ranks #463 out of 1130 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Ligand Pharmaceuticals has a GF Score™ of 76/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ligand Pharmaceuticals' 3-Year EBITDA Growth Rate compare to CGON and DFTX?
According to the Biotechnology industry distribution chart, Ligand Pharmaceuticals ranks #463 out of 1130 companies for 3-Year EBITDA Growth Rate. This puts Ligand Pharmaceuticals in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.85. Ligand Pharmaceuticals' value of 22.50% is 51.5% above this benchmark. While the company's 10-year median is 17.45 vs. the industry median of 14.85, Ligand Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.85, based on 1,130 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ligand Pharmaceuticals's current 3-Year EBITDA Growth Rate of 22.50% is 51.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Ligand Pharmaceuticals and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ligand Pharmaceuticals's current 3-Year EBITDA Growth Rate is 22.50%, which is 29% above median its own 10-year median of 17.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ligand Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Ligand Pharmaceuticals (FRA:LGDN) is currently considered Significantly Overvalued. The stock's GF Value™ is €154.08, compared to a current price of €238.00 — trading 54.5% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 22.50%, which is 29% above median its 10-year median of 17.45 and 51.5% above the Biotechnology industry median of 14.85. Ligand Pharmaceuticals' overall GF Score™ is 76/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Ligand Pharmaceuticals (FRA:LGDN), the current 3-Year EBITDA Growth Rate is 22.50% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ligand Pharmaceuticals (FRA:LGDN) Overvalued in 2026?
Based on GuruFocus' analysis, Ligand Pharmaceuticals stock appears to be overvalued.
The current stock price of €238.00 is trading 54.5% above its estimated GF Value™ of €154.08.
GuruFocus considers Ligand Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for FRA:LGDN:
3-Year EBITDA Growth Rate: 22.50% (29% above median its 10-year median of 17.45)
GF Value™: €154.08 vs. price of €238.00 (54.5% above fair value)
Industry Position: 51.5% above the Biotechnology median (#463 of 1130)
No single metric tells the full story. See the FRA:LGDN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
76GF Score
Get the complete analysis for FRA:LGDN
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:LGDN has been successfully added to your 
